Otello Stampacchia Biography and Net Worth

Director of ImageneBio

Dr. Stampacchia has served as a member of the Ikena board since December 2020. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Funds LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previously served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc.(NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbourg. We believe Dr. Stampacchia is qualified to serve on the Ikena board because of his venture capital experience in the life sciences industry and his service on the boards of directors of other public and private life sciences companies.

What is Otello Stampacchia's net worth?: The estimated net worth of Otello Stampacchia is at least $2.21 million as of July 25th, 2025. Dr. Stampacchia owns 454,982 shares of ImageneBio stock worth more than $2,214,852 as of September 23rd. This net worth evaluation does not reflect any other investments that Dr. Stampacchia may own. Learn More about Otello Stampacchia's net worth.
How do I contact Otello Stampacchia?: The corporate mailing address for Dr. Stampacchia and other ImageneBio executives is 12526 High Bluff Drive, San Diego, CA, 92130. ImageneBio can also be reached via phone at (857) 343-8292 and via email at [email protected]. Learn More on Otello Stampacchia's contact information.
Has Otello Stampacchia been buying or selling shares of ImageneBio?: Otello Stampacchia has not been actively trading shares of ImageneBio during the last ninety days. Most recently, on Friday, July 25th, Otello Stampacchia bought 267,556 shares of ImageneBio stock. The stock was acquired at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the completion of the transaction, the director now directly owns 454,982 shares of the company's stock, valued at $13,603,961.80. Learn More on Otello Stampacchia's trading history.
Who are ImageneBio's active insiders?: ImageneBio's insider roster includes David Bonita (Director), Jean-Francois Formela (Director), Otello Stampacchia (Director), and Michelle Zhang (Insider). Learn More on ImageneBio's active insiders.
Are insiders buying or selling shares of ImageneBio?: During the last year, ImageneBio insiders bought shares 1 times. They purchased a total of 16,000 shares worth more than $95,840.00. The most recent insider tranaction occured on December, 24th when Director Joseph P Slattery bought 16,000 shares worth more than $95,840.00. Insiders at ImageneBio own 2.2% of the company. Learn More about insider trades at ImageneBio.
Information on this page was last updated on 12/24/2025.

Otello Stampacchia Insider Trading History at ImageneBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/25/2025	Buy	267,556	$29.90	$7,999,924.40	454,982

Otello Stampacchia Buying and Selling Activity at ImageneBio

ImageneBio Company Overview

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Today's Range

Now: $4.87

$4.81

$4.98

50 Day Range

MA: $5.42

$4.81

$6.01

2 Week Range

Now: $4.87

$3.94

$9.10

Volume

1,479 shs

Average Volume

134,705 shs

Market Capitalization

$55.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7